Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis.
作者信息
Hayward Kelly L, Bansal Vikas, Valery Patricia C, Irvine Katharine M, Wright Penny L, Tallis Caroline J, Stuart Katherine A, Cottrell W Neil, Martin Jennifer H, Powell Elizabeth E
机构信息
Centre for Liver Disease Research, Translational Research InstituteThe University of QueenslandWoolloongabba, BrisbaneQueenslandAustralia.
Department of Gastroenterology and HepatologyPrincess Alexandra HospitalWoolloongabba, BrisbaneQueenslandAustralia.
出版信息
Hepatol Commun. 2022 Nov;6(11):3281-3282. doi: 10.1002/hep4.1999. Epub 2022 May 13.
Abstract
摘要
相似文献
1
Patient-oriented medication education intervention has long-term benefits for people with decompensated cirrhosis.以患者为导向的药物治疗教育干预对失代偿期肝硬化患者具有长期益处。
Hepatol Commun. 2022 Nov;6(11):3281-3282. doi: 10.1002/hep4.1999. Epub 2022 May 13.
2
Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.抗病毒治疗应答对慢性乙型肝炎病毒感染伴失代偿期肝硬化患者短期和长期结局的影响。
Clin Gastroenterol Hepatol. 2018 Dec;16(12):1954-1963.e3. doi: 10.1016/j.cgh.2018.04.063. Epub 2018 May 9.
3
DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.直接抗病毒药物治疗与晚期/失代偿期肝硬化的长期肝功能：HCV-TARGET 队列的真实世界经验。
J Hepatol. 2020 Sep;73(3):540-548. doi: 10.1016/j.jhep.2020.03.031. Epub 2020 Mar 31.
4
Antiviral therapy for hepatitis B virus-related decompensated cirrhosis.乙型肝炎病毒相关失代偿性肝硬化的抗病毒治疗。
J Dig Dis. 2012 Nov;13(11):555-7. doi: 10.1111/j.1751-2980.2012.00630.x.
5
Patient-oriented education and medication management intervention for people with decompensated cirrhosis: study protocol for a randomized controlled trial.针对失代偿期肝硬化患者的以患者为导向的教育与药物管理干预：一项随机对照试验的研究方案
Trials. 2017 Jul 20;18(1):339. doi: 10.1186/s13063-017-2075-4.
6
Effectiveness of patient-oriented education and medication management intervention in people with decompensated cirrhosis.以患者为中心的教育和药物管理干预对失代偿期肝硬化患者的效果。
Intern Med J. 2020 Sep;50(9):1142-1146. doi: 10.1111/imj.14986.
7
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy.乙型肝炎病毒相关失代偿期肝硬化：抗病毒治疗的获益。
J Hepatol. 2012 Aug;57(2):442-50. doi: 10.1016/j.jhep.2012.02.033. Epub 2012 Apr 12.
8
Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.直接作用抗病毒治疗对慢性丙型肝炎失代偿期肝硬化患者的影响。
J Hepatol. 2016 Jun;64(6):1224-31. doi: 10.1016/j.jhep.2016.01.029. Epub 2016 Jan 30.
9
Recompensation of Decompensated Hepatitis B Cirrhosis: Current Status and Challenges.代偿期乙型肝炎肝硬化的补偿：现状与挑战。
Biomed Res Int. 2020 Sep 21;2020:9609731. doi: 10.1155/2020/9609731. eCollection 2020.
10
Antiviral therapy of decompensated hepatitis B virus-related cirrhosis.乙型肝炎病毒相关失代偿期肝硬化的抗病毒治疗。
Chin Med J (Engl). 2012 Jan;125(2):373-7.
引用本文的文献
1
Screening high-risk Veterans for cirrhosis: taking a stepwise population health approach.对高危退伍军人进行肝硬化筛查：采取循序渐进的人群健康方法。
BMC Health Serv Res. 2025 Jan 29;25(1):168. doi: 10.1186/s12913-025-12216-8.
Zotero 插件